title: Validation of an enhanced International Prognostic Index (NCCN-IPI) in an Asian cohort of patients with diffuse large B cell lymphoma.
authors.affiliation: Division of Hematology Oncology, Department of Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan.
authors.forename: Cih-En
authors.initials: CE
authors.lastname: Huang
authors.forename: Yi-Yang
authors.initials: YY
authors.lastname: Chen
authors.forename: Chang-Hsien
authors.initials: CH
authors.lastname: Lu
authors.forename: Pin-Tsung
authors.initials: PT
authors.lastname: Chen
authors.forename: Kuan-Der
authors.initials: KD
authors.lastname: Lee
authors.forename: Chih-Cheng
authors.initials: CC
authors.lastname: Chen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D044466:Asian People / Q000208:ethnology*; D015331:Cohort Studies; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D038622:Internationality; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000188:drug therapy / Q000208:ethnology*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D000069283:Rituximab; D015996:Survival Rate / Q000639:trends; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone